Leukemia & lymphoma/Leukemia and lymphoma · 2018 · 29 citations · 39 references
Life SciencesMolecular BiologyOncologyGene ExpressionMolecular OncologyOncogenesCancer BiomarkersImmuno-oncology BiomarkersMicrorna BiologyMicrorna-mediated RegulationNoncoding Rna BiologyNoncoding Rna In CancerCirculating MicrornasDisease-associated MicrornasMicrorna BiomarkersMicrorna Function In CancerMicrorna In CancerMicrorna Prognostic MarkersOutcome PredictionPrognostic Biomarker Discovery
MicroRNA-92a-3p (miR-92a-3p) derives from the oncogenic miR-17/92 cluster and its highly homologous miR-106a/363 cluster. miR-92a-3p regulates the expression of key transcription factors such as HIF1 and inhibits SOCS1 to enhance the anti-apoptotic STAT3/IL6 signaling pathway. In this study, we assessed the putative usefulness of miR-92a-3p as a prognostic and/or diagnostic biomarker in chronic lymphocytic leukemia (CLL). For this purpose, total RNA was extracted from mononuclear cells isolated from the peripheral blood of 88 CLL patients and 36 non-leukemic blood donors, was polyadenylated and reversely transcribed. miR-92a-3p expression was quantified using an accurate qPCR method. miR-92a-3p levels were significantly lower in peripheral blood mononuclear cells of CLL patients. Overall survival (OS) analysis revealed that high miR-92a-3p expression predicts significantly prolonged OS of CLL patients. Interestingly, miR-92a-3p overexpression remains a significant prognosticator in subgroups of CLL patients with distinct prognosis. In conclusion, miR-92a-3p overexpression is a potential surrogate biomarker of favorable outcome of CLL patients.
39
MicroRNA expression profiles classify human cancers
Jun Lü, Gad Getz, Eric A. Miska et al. · Nature · 2005 · 9.6K citations
George A. Calin, Calin Dan Dumitru, Masayoshi Shimizu et al. · Proceedings of the National Academy of Sciences · 2002 · 5K citations · Full text